Skip to main content

Temporary Change in Status for Platelet Aggregation Inhibitors Drug Classes

Last updated on 6/1/2020

On May 27, 2020, the Vendor Drug Program temporarily revised the Preferred Drug List to address reported possible drug shortages of products in the Platelet Aggregation Inhibitors drug class.

The change allows providers to prescribe these drugs without requiring a non-preferred prior authorization and people enrolled in Medicaid continued access to necessary medication. This is a temporary change until the preferred products are sufficiently available in the market. A list of the affected drugs is available on the Vendor Drug Program website.

Contact with questions or for more information.